793-1 Local, Low Pressure Heparin Delivery Following Angioplasty in Man: The Solution to Restenosls?  by Camenzind, Edoardo et al.
376A ABSTRAcrs lACC February 1995
Local Drug Delivery
Wednesday, March 22, 1995,2:00 p.m.-3:30 p.m.
Ernest N. Morial Convention Center, Room 26
PCNA (7 dayslt A-Xa (units/mll
Media Intima 1hour 24 hours
CO 4.04 ± 2.6 25.5 ± 8.4 0.02 ± 0.03 0.06 ± 007
LOC 4.8 ± 4.1 16.9 ± 11.9ttt 1.25 ± 0.27* 0.12±005
COM 1.6 ± 2.2tt 7.3 ± 9.2tttt 1.43 ± 0.12* 0.20 ± 0.10**
2:45
t (+) PCNA nuciei/JLm2; ttp = 0.06 vs. CO; tttp = 0.09 vs. CO; ttttp = 0.001 vs CO;
*p > 0.005 vs. CO; **p > 0.05 vs. CO
We conclude that: (1) Locally delivered enoxaparin tended to reduce
smooth muscle cell proliferation, and significantly inhibited smooth mus-
cle cell proliferation with concomitant systemic enoxaparin treatment, as
assessed by PCNA staining; (2) Supporting local enoxaparin effect with sys-
temic treatment at critical time point for smooth muscle cell proliferation
seems necessary: and (3) anti-Factor Xa activity levels suggest sustained
(up to 24 hours) enoxaparin activity only with combined local and systemic
treatment.
1793-41 Local Delivery of C-myb Antisense attenuates
Neo-Intimal Thickening In a Porcine Model of
Coronary Angioplasty
Julian Gunn, Cathy M. Holt, Lynda Shepherd, Sheila E. Francis, Geoffrey H. Smith,
David C. Cum berla nd Sections of Cardiac Surgery and Cardiology, University of
Sheffield, Northern General Hospital, Sheffield, UK
Intimal smooth muscle cell proliferation and extracellular matrix production
compose the restenotic lesion. The proto-oncogene c-myb is up-regulated
in proliferating cells and is a common "downstream" link in several mito-
genic pathways. We have recently shown that c-myb antisense specifically
inhibits proliferation of several types of human vascular cells in vitro. The de-
velopment of catheter-based local drug delivery systems allows us to test
the feasibility and efficacy of local intra-mural delivery of c-myb antisense in
a porcine model of coronary angioplasty
We first tested an unmodified HPLC-purified 18-mer antisense oligonu-
cleotide directed against the human sequence of c-myb in porcine aortic
smooth muscle cells in culture. More than 90% inhibition of cellular prolifer-
ation was observed at 5 JLM with no adverse effect on cellular viability. This
effect was not seen with sense oligonucleotides.
The in vivo delivery system used was the Transport (CVD) double skinned
balloon catheter, allowing high pressure oversized balloon dilatation followed
by low pressure delivery of 500 JLg antisense in 2 ml saline over 1 - 2 mins.
Ex vivo and in vivo delivery of fluorescein labelled oligonucleotide using this
system demonstrated successful intramural localisation. Wethen performed
oligo delivery in vivo into a single porcine coronary artery (n = 10); the con-
trol group underwent angioplasty using a conventional balloon without drug
delivery (n = 12). Animals were sacrificed at 4 weeks. Quantitative morpho-
metric analysis of serial transverse histological sections demonstrated a con-
sistent reduction in absolute and percent intimal thicknesses and areas to-
gether with a significant reduction in mean (SEM) intimal/medial thickness
ratio from 0.37 (0.09) to 0.1310.03) (p < 0.05) in the treatment group.
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o. Tahlil, P Erbacher, M. Brami, J.Y. Scoazec, A.C. Roche, A. Legrand, J,J. Barry,
M. Monsigny, P Midoux, PG. Steg. Faculte X Sichat, Paris & CNRS-Universite
d'OrMans, FR
Gene therapy for restenosis requires efficient and safe percutaneous gene
transfer to medial cells, Adenoviral vectors may not be absolutely safe, and,
most non-viral methods (such as direct DNA transfer or liposomes) for arterial
gene transfer have a very low efficiency, We sought to determine whether the
use of plasmid-polylysine complexes, associated with treatments designed
to prevent lysosomal degradation (such as chloroquine) could be used for
percutaneous local arterial gene transfer to the media using hydrogel-coated
balloons. 16 rabbits underwent iliac transluminal angioplasty using a 3,0 mm
hydrogel-coated balloon, with a 30 min inflation, The hydrogel had been
coated with 25 JLI of a plasmid-polylysine complex (containing 5 JLg DNA
of the pgalactosidase reporter gene driven by the SV40 promoter) and with
chloroquine (100 JLM). Rabbits were sacrificed at 3 days, and arteries (and
other organs) assayed for reporter gene expression by X-gal staining. In all
the animals, expression of the transgene was visible on macro and micro-
scopic examinations. It was strictly confined to the media in the target arterial
segment.
Conclusion: Percutaneous site-specific arterial gene transfer to the media
can be achieved using plasmid-polylysine complexes and chloroquine deliv-
ered via a hydrogel-coated angioplasty balloon.
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Conclusion: Local, low pressure heparin delivery following balloon angio-
plasty may reduce incidence of restenosis and decrease the need for re-
angioplasty.
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Edoardo Camenzind, Wim van der Giesen, Jurgen Ligthart, Peter Ruygrok,
Peter de Jaegere, Pim de Feyter, Patrick W. Serruys. Thoraxcentre, Erasmus
University, Rotterdam, Netherlands
Of 38 patients (28 men, 58 ± 10 years) treated by conventional balloon an-
gioplasty followed by local heparin delivery (1660 ± 656 IU at low pressure
110 ± 48 mmHg during 30 ± 7 min) through the Dispatch 'w (Scimed) 20 (12
men, 57 ± 10 years). have undergone 6 month review. One 78 year old pa-
tient with aortic stenosis died in hospital 7 weeks after the procedure from
acute heart failure following 2 transfusions for the exacerbation of ulcerative
colitis. Of the 19 remaining patients clinical follow-up was available for all
and control angiography was performed in 14 (74%), Of the 5 who declined,
all asymptomatic, 3 had a negative MIBI scintigram and 2 refused further
examination. Symptoms: Five (26%) of the 19 patients were symptomatic
(3 exertional and 2 atypical angina) and angiography showed 4 new lesions
and 1 restenosis (diameter stenosis 60%) of the target lesion, Angiogram:
No aneurysmatic dilatation at the site of delivery was visualized, However
4 out of 14 (29%) lesions had a increase in MLD (range: 0.17-0,51 mm).
Mean MLD measured by quantitative analysis (CAAS II) in matched projec-
tions (post-procedure vs 6 month follow-up) was 2,0 ± 0.5 mm vs 1.73 ±
0.4 mm representing a mean late loss of 0.27 mm. The incidence of resteno-
sis, defined as a diameter stenosis at follow-up of >50% was 7%. None of
patients required re-angioplasty of the treated segment.
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Alexey Tjurmin, James J. Barry, Myong H. Nam, Theodore E. Spiro, Martin B. Leon
Washington Hospital Center. Washington, D. C.; American Red Cross, Rockville, MD
Enoxaparin (EN), when systemically administered, has been shown to re-
duce restenosis in preclinical studies. Previously, we demonstrated that 3H_
EN locally delivered via channeled balloon (CB), a dual-purpose local deliv-
ery catheter capable of simultaneous angioplasty, was retained intramurally
for at least 24 hours, To determine whether locally delivered EN can reduce
restenosis by inhibiting smooth muscle cell proliferation, 3 groups of rab-
bits underwent balloon injury of bilateral iliac arteries with CB (balloon/artery
= 1.1), followed by assigned treatment [4 control rabbits (CO) receiving lo-
cal saline in 8 arteries, 4 local EN rabbits (LOC) receiving one-time local EN
@ 10 mglkg at the time of angioplasty in 8 arteries, and 5 combined treat-
ment rabbits (COM) receiving one-time local EN @ 10 mglkg in 10 arteries
and systemic EN @ 10 mglkg s.c. daily for one week). One week later, the
animals were euthanized and the iliac arteries were perfusion fixed for prolif-
erating cell nuclear antigen (PCNA) staining, Anti-factor Xa activity (A-Xa) as a
measure of successful EN delivery was measured at baseline (0.024 ± 0.02
units/ml), 1 hour and 24 hours after the procedure.
